Faron, etusivu

releases and publications

Faron’s Financial Calendar for 2023

BEXMAB Study Update

Regulatory

Faron Appoints Maija Hollmén PhD as CSO

Regulatory

Amendment Terms and Conditions with IPF Partners

Regulatory

Faron Announces Poster Presentation at SITC

BEXMAB Study Update

Regulatory

Holding(s) in Company

Shareholder announcement Regulatory

Holding(s) in Company

Shareholder announcement Regulatory

Faron Pharmaceuticals Presents Results from PD-1 Blockade Refractory Melanoma Cohort of MATINS Trial at 19th International Congress of The Society for Melanoma Research

Results of Placing

Regulatory
PreviousNext
Back to top